Press Releases

10th September 2019 Paras Biopharmaceuticals - Successful Development of Cytofold StructQuant® Technology
7th May 2019: Reuters to make a documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a leading expert.
1st February, 2019: Paras Biopharmaceuticals Finland Oy Announces Successful Development of Biologically Active Romiplostim (N-Plate® Biosimilar) Production Technology
9th October, 2018: Affordable Healthcare in Oulu Closer than Ever: Paras Biopharmaceuticals Finland Oy Significantly Invests in Oulu Biologics Production Site
12th December 2016: Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland
25th August 2016: Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.
24th November 2015: Paras Biopharmaceuticals forms partnership with Novozymes to embrace Veltis® technology for once-a-week Teriparatide Biobetter for Osteoporosis
28th April 2015: Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum
11th December 2014: Paras Biopharmaceuticals wins the 2014 European Biopharmaceuticals Technology Innovation Leadership Award by Frost & Sullivan

To view award report, click on the link below

Award Report

*NEW* Photos of Award Ceremony and Banquet

Media Contact

Dr. Mark Jackson
Public Affairs

Meet Us At

Connect with us

Paras Biopharmaceuticals
Finland Oy

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
P: +358 (0) 400207380

Dr Mark Jackson
P:+358 (0) 442905993

Skype: Paras.Finland